WuXi Biologics (Cayman) Inc. (WuXi Biologics) submitted its Securities Transactions Monthly Return for the period ended June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 5, 2024. The report shows that the company's legal/registered share capital remains at USD 10,000,000,000 with a par value of USD 0.00005 per share, totaling USD 500,000. During the same period, the total issued shares (excluding treasury shares) increased from 1,198,104,069 shares to 1,198,215,456 shares, an increase of 111,387 shares. The company's share option plan had been granted before the first public offering in 2021 and increased by 111,387 common shares during the month of June 2024 due to the exercise of the options, raising a total amount of CNY 184,679.6. There is no information about Hong Kong depository securities in the report and it is confirmed that all securities issuances comply with relevant listing rules and legal regulations.

WuXi Biologics (Cayman) Inc. (WuXi Biologics) submitted its Securities Transactions Monthly Return for the period ended June 30, 2024 to Hong Kong Exchanges and Clearing Limited on July 5, 2024. The report shows that the company's legal/registered share capital remains at USD 10,000,000,000 with a par value of USD 0.00005 per share, totaling USD 500,000. During the same period, the total issued shares (excluding treasury shares) increased from 1,198,104,069 shares to 1,198,215,456 shares, an increase of 111,387 shares. The company's share option plan had been granted before the first public offering in 2021 and increased by 111,387 common shares during the month of June 2024 due to the exercise of the options, raising a total amount of CNY 184,679.6. There is no information about Hong Kong depository securities in the report and it is confirmed that all securities issuances comply with relevant listing rules and legal regulations.